RNA, U1 small nuclear 82, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-82P profile across patient tissues and cancer cell-line models. RNU1-82P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RNU1-82P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RNU1-82P RNA expression shows 3,586 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, BRCA, and STAD as cancer lineages where RNU1-82P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-82P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-82P survival associations across molecular data types. RNU1-82P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-82P RNA expression–survival associations across cancer types. High RNU1-82P expression shows unfavorable associations in CHOL, UVM, ACC, ESCA, THYM and KIRP. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RNU1-82P RNA expression.
This table summarizes RNU1-82P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-82P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-82P shows higher tumor expression in BRCA. The BRCA box plot shows higher RNU1-82P RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .015).
This table shows molecular features associated with RNU1-82P in patient tissues and cancer cell lines. In patient samples, RNU1-82P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
